Researchers & Healthcare Professionals

www.lls.org/researchershealthcareprofessionals

Did you know?

LLS Therapy Acceleration Program partner, Celator, has completed their targeted enrollment of 120 first relapsed AML patients for their phase II trial of their liposomal drug CPX-351.

Blood Cancer Research Grants Finder

last updated on Wednesday, February 09, 2011
btn_sharethis